Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (51 quarters reported)
$127M in Q4 2013 → $1.1B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Liquidia Corporation | 17.7% | Trimmed 3.8% | 2,447,500 | $195M |
| Eton Pharmaceuticals Inc | 9.4% | Unchanged | 2,860,000 | $104M |
| Harrow Inc | 9.2% | Trimmed 15% | 2,400,000 | $102M |
| Disc Medicine Inc | 5.7% | Added 103% | 855,000 | $62.5M |
| Urogen Pharma Ltd | 4.8% | Added 0.7% | 1,439,996 | $53M |
| Apogee Therapeutics Inc | 4.7% | Unchanged | 390,000 | $51.8M |
| MH Meiragtx Hldgs PLC | 4.3% | Added 67% | 3,550,000 | $48M |
| Sol-gel Technologies Ltd | 3.4% | Unchanged | 500,000 | $37.1M |
| Rezolute Inc | 3.0% | Unchanged | 6,300,000 | $32.8M |
| Tg Therapeutics Inc | 2.7% | Unchanged | 535,000 | $29.4M |
| Immix Biopharma Inc | 2.2% | New | 2,345,000 | $24.2M |
| Crescent Biopharma Inc. | 2.2% | Added 0.5% | 1,319,351 | $23.7M |
| Stoke Therapeutics Inc | 2.1% | Unchanged | 700,000 | $22.9M |
| Alpha Cognition Inc | 1.9% | Added 13% | 2,895,467 | $20.9M |
| Edgewise Therapeutics Inc | 1.8% | Unchanged | 500,000 | $20.3M |
| Revolution Medicines Inc | 1.7% | Unchanged | 100,000 | $18.7M |
| Monte Rosa Therapeutics Inc | 1.6% | New | 745,000 | $18M |
| Alumis Inc | 1.4% | Unchanged | 550,000 | $15.5M |
| Codexis Inc | 1.4% | Unchanged | 6,785,000 | $15.3M |
| Replimune Group Inc | 1.4% | New | 1,384,993 | $15.3M |
| Xoma Royalty Corporation | 1.3% | Added 13% | 338,374 | $14.4M |
| Mbx Biosciences Inc | 1.3% | Unchanged | 260,000 | $14.4M |
| Rhythm Pharmaceuticals Inc | 1.2% | Trimmed 0.4% | 122,500 | $13.6M |
| Editas Medicine Inc | 1.1% | Added 100% | 3,861,930 | $12.5M |
| Protagonist Therapeutics Inc | 1.1% | Unchanged | 100,000 | $12.3M |
| Cabaletta Bio Inc | 1.1% | Added 180% | 3,863,800 | $12M |
| Q32 Bio Inc | 1.1% | Trimmed 26% | 931,000 | $11.9M |
| Annexon Inc | 0.9% | Trimmed 26% | 1,714,451 | $9.79M |
| Verastem Inc | 0.6% | New | 1,800,000 | $6.88M |
| Zentalis Pharmaceuticals Inc | 0.6% | Unchanged | 1,412,656 | $6.85M |
| Relmada Therapeutics Inc | 0.6% | Unchanged | 935,000 | $6.47M |
| Ocular Therapeutix Inc | 0.5% | Unchanged | 600,000 | $5.89M |
| Trevi Therapeutics Inc | 0.5% | Trimmed 10% | 310,000 | $5.78M |
| BO Bridgebio Oncology Therapeut | 0.5% | Added 1214% | 700,000 | $5.33M |
| Lyell Immunopharma Inc | 0.4% | Added 335% | 344,025 | $4.83M |
| Opus Genetics Inc | 0.4% | Added 0.4% | 1,125,000 | $4.62M |
| 4M 4d Molecular Therapeutics In | 0.4% | Added 198% | 334,437 | $4.45M |
| Intellia Therapeutics Inc | 0.4% | Added 2.0% | 250,000 | $4.23M |
| Voyager Therapeutics Inc | 0.4% | Added 3.0% | 1,185,000 | $4.15M |
| Biodesix Inc | 0.4% | Trimmed 24% | 180,000 | $4.06M |
| Rocket Pharmaceuticals Inc | 0.3% | Added 4.7% | 1,000,000 | $3.42M |
| Jade Biosciences Inc | 0.3% | Trimmed 66% | 145,000 | $3.22M |
| Sanuwave Health Inc | 0.3% | Trimmed 69% | 306,140 | $3.06M |
| Fortress Biotech Inc | 0.2% | Trimmed 15% | 890,000 | $2.72M |
| JM Journey Med Corp | 0.2% | Trimmed 64% | 350,000 | $2.48M |
| Phathom Pharmaceuticals Inc | 0.2% | New | 185,589 | $2.01M |
| Inhibrx Biosciences Inc | 0.2% | New | 20,291 | $1.92M |
| Enanta Pharmaceuticals Inc | 0.2% | Unchanged | 125,000 | $1.82M |
| HT Hemab Therapeutics Hldgs Inc | 0.2% | New | 47,652 | $1.75M |
| First Tracks Biotherapeutics | 0.1% | New | 65,000 | $1.31M |
| Cg Oncology Inc | 0.1% | Trimmed 81% | 17,789 | $1.26M |
| Biohaven Ltd | 0.1% | New | 77,915 | $1.16M |
| Atea Pharmaceuticals Inc | 0.1% | Trimmed 27% | 235,000 | $1.09M |
| Pasithea Therapeutics Corp | 0.1% | New | 2,050,000 | $1.06M |
| AT Adc Therapeutics Sa | 0.1% | New | 700,000 | $749K |
| Okyo Pharma Ltd | 0.1% | New | 375,204 | $563K |
| Palatin Technologies Inc | 0.0% | New | 20,500 | $221K |
| AM Adagio Med Hldgs Inc | 0.0% | Unchanged | 18,444 | $13.4K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Disc Medicine Inc | Added | +434,000 | +$31.7M | 5.7% |
| Immix Biopharma Inc | New | +2,345,000 | +$24.2M | 2.2% |
| Perspective Therapeutics Inc | Exited | −4,675,000 | −$19.5M | — |
| MH Meiragtx Hldgs PLC | Added | +1,426,741 | +$19.3M | 4.3% |
| Harrow Inc | Trimmed | −432,230 | −$18.4M | 9.2% |
| Monte Rosa Therapeutics Inc | New | +745,000 | +$18M | 1.6% |
| Replimune Group Inc | New | +1,384,993 | +$15.3M | 1.4% |
| Liquidia Corporation | Trimmed | −97,500 | −$7.77M | 17.7% |
| Cabaletta Bio Inc | Added | +2,483,800 | +$7.72M | 1.1% |
| Verastem Inc | New | +1,800,000 | +$6.88M | 0.6% |
Showing the 10 largest of 50 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | Trimmed | −207,000 | −$59.4M | 4.7% |
| Harrow Inc | Trimmed | −1,072,770 | −$37.8M | 13.2% |
| Cg Oncology Inc | Trimmed | −315,200 | −$21.3M | 0.8% |
| Urogen Pharma Ltd | Added | +1,161,577 | +$20.9M | 3.4% |
| MH Meiragtx Hldgs PLC | Added | +1,732,415 | +$15M | 2.4% |
| Perspective Therapeutics Inc | Added | +3,490,500 | +$14.6M | 2.6% |
| Disc Medicine Inc | Added | +221,000 | +$14.1M | 3.5% |
| Alkermes PLC | Exited | −490,000 | −$13.7M | — |
| Gossamer Bio Inc | Exited | −2,720,000 | −$8.43M | — |
| Ocular Therapeutix Inc | Trimmed | −995,000 | −$8.43M | 0.7% |
Showing the 10 largest of 50 changes.
quarter ended December 31, 2025 · filed April 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Immunome Inc | Exited | −3,185,000 | −$37.3M | — |
| Rhythm Pharmaceuticals Inc | Trimmed | −131,700 | −$14.1M | 4.7% |
| Crescent Biopharma Inc | New | +1,178,300 | +$14M | 1.8% |
| Alpha Cognition Inc | Added | +1,955,642 | +$12.7M | 1.8% |
| Rezolute Inc | Added | +5,383,714 | +$12.7M | 2.0% |
| Sarepta Therapeutics Inc | Exited | −585,000 | −$11.3M | — |
| Larimar Therapeutics Inc | Exited | −3,720,867 | −$10.6M | — |
| Sol Gel Technologies | Added | +248,904 | +$10.5M | 2.5% |
| Codexis Inc | Trimmed | −6,005,262 | −$9.79M | 1.5% |
| Arvinas Inc | Exited | −987,818 | −$8.42M | — |
Showing the 10 largest of 55 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Apogee Therapeutics Inc | New | +363,257 | +$14.4M | 2.0% |
| Alkermes PLC | New | +450,000 | +$13.5M | 1.9% |
| VN Vigil Neurosciences Inc | Exited | −1,000,000 | −$7.95M | — |
| Annexon Inc | New | +2,600,000 | +$7.93M | 1.1% |
| Journey Medical Corp | Added | +876,064 | +$6.24M | 1.0% |
| Anika Therapeutics Inc | Exited | −588,797 | −$6.23M | — |
| Sol Gel Technologies | New | +204,835 | +$5.97M | 0.8% |
| Gossamer Bio Inc | Exited | −11,500,000 | −$5.95M | — |
| Arvinas Inc | Trimmed | −692,182 | −$5.9M | 1.2% |
| Cg Oncology Inc | Added | +144,000 | +$5.8M | 2.3% |
Showing the 10 largest of 40 changes.
quarter ended June 30, 2025 · filed August 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sarepta Therapeutics Inc | New | +500,000 | +$8.55M | 1.7% |
| VN Vigil Neurosciences Inc | New | +1,000,000 | +$7.95M | 1.6% |
| Ginkgo Bioworks Holdings | Trimmed | −695,000 | −$7.82M | 1.1% |
| Codexis Inc | Added | +3,100,000 | +$7.56M | 6.2% |
| Larimar Therapeutics Inc | Added | +2,195,923 | +$6.35M | 2.4% |
| Disc Medicine Inc | Added | +101,418 | +$5.37M | 2.0% |
| Palvella Therapeutics Inc | Exited | −172,357 | −$4.82M | — |
| AB Anaptys Bio Inc | Exited | −250,933 | −$4.66M | — |
| Acelyrin Inc | Exited | −1,615,000 | −$3.99M | — |
| Revolution Medicines Inc | New | +105,000 | +$3.86M | 0.8% |
Showing the 10 largest of 41 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tg Therapeutics Inc | Trimmed | −1,725,000 | −$68M | 4.7% |
| Sanuwave Health Inc | New | +972,002 | +$34.4M | 7.7% |
| Ocular Therapeutix Inc | Trimmed | −2,747,500 | −$20.1M | 2.6% |
| Immunome Inc | Added | +1,510,000 | +$10.2M | 5.3% |
| Trevi Therapeutics Inc | Trimmed | −1,522,500 | −$9.58M | 1.1% |
| Jasper Therapeutics Inc | Exited | −400,000 | −$8.55M | — |
| NP Newamsterdam Pharma Company | Exited | −325,000 | −$8.35M | — |
| Liquidia Corporation | Added | +561,858 | +$8.29M | 7.4% |
| Vaxcyte Inc | Exited | −75,000 | −$6.14M | — |
| Anika Therapeutics Inc | New | +395,000 | +$5.94M | 1.3% |
Showing the 10 largest of 46 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Keros Therapeutics Inc | Exited | −395,276 | −$23M | — |
| Applied Therapeutics Inc' | Exited | −1,320,000 | −$11.2M | — |
| Immunome Inc | Added | +802,500 | +$8.52M | 3.8% |
| Arvinas Inc | Added | +370,000 | +$7.66M | 5.9% |
| Ocular Therapeutix Inc | Trimmed | −682,500 | −$5.83M | 6.5% |
| Cytokinetics Inc | Exited | −75,300 | −$3.98M | — |
| Essa Pharma Inc | New | +2,209,998 | +$3.96M | 0.7% |
| Ginkgo Bioworks Holdings | Added | +379,798 | +$3.73M | 2.1% |
| Cargo Therapeutics Inc | Added | +208,563 | +$3.01M | 1.9% |
| Zentalis Pharmaceuticals Inc | Added | +800,500 | +$2.43M | 0.9% |
Showing the 10 largest of 42 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arvinas Inc | Added | +700,000 | +$17.2M | 5.2% |
| Codexis Inc | Added | +5,315,000 | +$16.4M | 4.5% |
| Liquidia Corporation | Added | +1,373,142 | +$13.7M | 2.8% |
| Catalyst Pharmaceuticals Inc | Trimmed | −527,500 | −$10.5M | 0.4% |
| 4d Molecular Therapeutics Inc | Exited | −345,750 | −$7.26M | — |
| Iovance Biotherapeutics Inc | Exited | −897,000 | −$7.19M | — |
| Ginkgo Bioworks Holdings | New | +820,202 | +$6.68M | 1.1% |
| Cytokinetics Inc | Trimmed | −123,200 | −$6.5M | 0.7% |
| Intellia Therapeutics Inc | Exited | −218,000 | −$4.88M | — |
| Zentalis Pharmaceuticals Inc | New | +967,000 | +$3.56M | 0.6% |
Showing the 10 largest of 48 changes.
Loading...
